BTT vs SNDX Comparison

Blackrock Municipal 2030 Target Term Trust is a United States-based fixed-term, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and to return $25.00 per common share to common shareholders at maturity. The Fund invests the majority of its managed assets in investment-grade municipal securities, the interest of which is exempt from regular federal income tax, and derivatives that provide investment exposure to such securities or to one or more market risk factors associated with such securities.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.